Long‐Term Migraine Prevention With Topiramate: Open‐Label Extension of Pivotal Trials
Authors:
- Alexander MauskopAMAlexander Mauskop
- Hans‐Christoph DienerHDHans‐Christoph Diener
- Susanne SchwalenSSSusanne Schwalen
- Joop PfeilJPJoop Pfeil
- 6 July 2006
- journal article
- research article
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 46 (7) , 1151-1160
Abstract
Objective.—To demonstrate that topiramate is an effective and generally well‐tolerated migraine preventive therapy when used for up to 14 months. Background.—Topiramate 100 and 200 mg/d significantly reduced mean monthly migraine frequency during 2 large, 26‐week, randomized, placebo‐controlled trials. Only a small number of clinical trials have examined the long‐term (≥1 year) effectiveness and safety of migraine preventive therapies. Methods.—Five hundred sixty‐seven patients with an established history of migraine with or without aura were enrolled in this 8‐month, open‐label extension of 2 large (49 US and 52 US and Canadian medical centers), randomized, double‐blind, placebo‐controlled, parallel group, 26‐week trials of identical design. To be eligible for the open‐label extension, patients were required to have either completed the double‐blind phase of the 2 pivotal migraine prevention trials or withdrew after 4 weeks due to lack of efficacy. All eligible patients, regardless of type or dose of study medication (topiramate or placebo) received in the double‐blind phase, were titrated to a clinically effective dose of open‐label topiramate based on physician judgment of patient response. Efficacy of topiramate was measured as the change in mean monthly migraine frequency. Results.—The mean topiramate dose during the open‐label extension phase was 124.7 mg/d and 150.3 mg/d for patients on placebo (n = 159) or topiramate (n = 408), respectively, during the double‐blind phase (N = 567, 91% female, mean age 39.4 years). Patients on topiramate for up to 14 months had 2.2 ± 2.4 (mean ± SD) migraines per month after completion of the open‐label extension phase (3.4 ± 2.6 at double‐blind endpoint). Patients on topiramate during the open‐label extension phase only (placebo during the double‐blind phase) had 3.0 ± 2.9 migraines per month at open‐label extension endpoint (4.9 ± 3.0 migraines per month at double‐blind endpoint). Discontinuation rates due to adverse events during the double‐blind phase were 22.2% for patients on topiramate and 11.0% for patients on placebo. Discontinuation rates due to adverse events during the open‐label extension phase were 8.6% for those patients who had already received topiramate during the double‐blind phase and 20.9% for those patients who had previously received placebo. Conclusions.—Patients receiving topiramate experienced a sustained reduction in migraine frequency for up to 14 months. The effectiveness and safety of topiramate was consistent with that observed during 2 26‐week pivotal trials.Keywords
This publication has 17 references indexed in Scilit:
- Characterization and Prediction of Emergency Department Use in Chronic Daily Headache PatientsHeadache: The Journal of Head and Face Pain, 2005
- Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydraseEpilepsy Research, 2005
- Topiramate in migraine prophylaxisJournal of Neurology, 2004
- Propranolol for migraine prophylaxis2004
- Topiramate in Migraine PreventionArchives of Neurology, 2004
- Topiramate for Migraine PreventionA Randomized Controlled TrialJAMA, 2004
- Topiramate alters excitatory synaptic transmission in mouse hippocampusEpilepsy Research, 2003
- Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine HeadacheAnnals of Internal Medicine, 2002
- Burden of Migraine in the United StatesArchives of internal medicine (1960), 1999
- Post-Marketing Cohort Study Comparing the Safety and Efficacy of Flunarizine and Propranolol in the Prophylaxis of MigraineCephalalgia, 1996